Cargando…
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
PURPOSE: Cardiac dysfunction, particularly QT interval prolongation, has been observed with tyrosine kinase inhibitors approved to treat chronic myeloid leukemia. This study examines the effects of ponatinib on cardiac repolarization in patients with refractory hematological malignancies enrolled in...
Autores principales: | Sonnichsen, Daryl, Dorer, David J., Cortes, Jorge, Talpaz, Moshe, Deininger, Michael W., Shah, Neil P., Kantarjian, Hagop M., Bixby, Dale, Mauro, Michael J., Flinn, Ian W., Litwin, Jeffrey, Turner, Christopher D., Haluska, Frank G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668123/ https://www.ncbi.nlm.nih.gov/pubmed/23609479 http://dx.doi.org/10.1007/s00280-013-2160-7 |
Ejemplares similares
-
Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013) -
Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013) -
P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
por: Müller, Martin C., et al.
Publicado: (2023) -
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022) -
Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020)